Trillium Securityholders Approve Acquisition by Pfizer

Ontario Industry Updates
Written By Viktoriya Shabat

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced on October 26, that its securityholders approved a statutory arrangement with PF Argentum ULC a wholly-owned, indirect subsidiary of Pfizer Inc. at the special meeting of Trillium securityholders. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates.

Viktoriya Shabat
Previous

KixCare Raises $2M Seed Round to Revolutionize Canadian Pediatric Care
Next

EmergConnect Raises $350,000 to Fund Emergency Room Wait Time Predictor